Breast cancer survivor offers wisdom at Faulkner satellite center
Call 877-422-3324 today to make an appointment
Make your appointment or second opinion with Dana-Farber today to meet with an onsite specialist.
Can’t get to Boston? Explore our Online Second Opinion service to get expert advice from Dana-Farber oncologists.
Toll-Free Number866-408-DFCI (3324)
Discover the ways to give and how to get involved to support Dana-Farber.
Poet Richard Fox gains insight – and material – through cancer treatment
A family faces cancer in an unfamiliar city – with help
Choosing mastectomy or not: Studying young women's surgical choices
Jeff's targeted therapy has kept his advanced lung cancer at bay.
It's well known that the most significant risk factor for lung cancer is cigarette smoking. However, an estimated 8 percent of men and 20 percent of women with lung cancer are never-smokers. Currently, the causes of lung cancer in nonsmokers or never-smokers are not well understood.
A group of researchers at Dana-Farber is trying to understand whether inherited factors may partly explain the development of lung cancer in patients who did not smoke.
A small number of people are born with a DNA mutation in the EGFR gene called T790M, which has been identified in some families suffering from lung cancer. This T790M mutation is called germline, because it is present in all of the body's cells, most likely because it was inherited from a parent.
When doctors test a sample of tumor tissue from a patient diagnosed with lung cancer, and the sample contains the T790M mutation, this is an indication that the patient may be at risk for having this inherited T790M mutation.
Because individuals and families carrying the inherited T790M are rare, in December 2012 we launched a collaborative study aimed at identifying and studying these individuals in order to better understand the cause of lung cancer. Our hope is to find ways of reducing the chances that carriers of the T790M mutation will develop lung cancer. Study participants include smokers, former smokers, and non-smokers. Collecting such a registry of high risk families will lay the groundwork for subsequent lung cancer screening and prevention research.
Dr. Geoffrey Oxnard at Dana-Farber Cancer Institute is heading the study in collaboration with the Addario Lung Cancer Medical Institute (ALCMI), leading lung cancer research centers, and commercial gene-testing laboratories.
Take the eligibility survey for this research study.
If you'd like more information about this study, please email DFCIfamilialT790M@dfci.harvard.edu.